UFP Technologies to Report Fourth Quarter and Year-End 2025 Financial Results on February 24, 2026

UFP Technologies, Inc. (Nasdaq: UFPT), a prominent contract development and manufacturing organization, is set to announce its financial results for the fourth quarter and year-end of 2025 on February 24, 2026, following the close of the stock market. The company specializes in the creation of single-use and single-patient medical devices, playing a crucial role in the supply chain for medical device manufacturing.

On February 25, 2026, at 8:30 AM Eastern time, UFP Technologies will host a conference call to discuss its financial performance. This call is an opportunity for investors and interested parties to gain insights into the company's results and future direction. Participants can access the call by dialing 1-412-206-6478 within the USA and Canada or 1-833-890-4010 for international attendees. Additionally, a live webcast of the conference will be available, along with accompanying materials, on the company's Investor Relations webpage. A replay of the event will also be accessible after the call.

UFP Technologies is recognized as a key partner to many leading medical device manufacturers, providing essential products for various applications, including minimally invasive surgeries, infection prevention, wound care, and orthopedic solutions. As a valued outsourcing partner, the company supports the development of innovative healthcare solutions, emphasizing its commitment to quality and efficiency in medical device production.

Investors eager to learn about the company's financial performance and strategic outlook should take note of these upcoming events. For further inquiries, Jeff Elliott of Three Part Advisors, LLC, and Ron Lataille, CFO of UFP Technologies, are available for contact.

As UFP Technologies, Inc. approaches the announcement of its fourth quarter and year-end financial results on February 24, 2026, investors are poised to glean insights that could have significant implications for the stock’s performance. Given the company’s position as a contract development and manufacturing organization in the medical device sector, there are key factors to consider in the lead-up to this report.

Firstly, UFP’s commitment to specializing in single-use and single-patient medical devices places it strategically within a growing market responding to heightened demand for safety and infection control—from surgical settings to outpatient care. Investors should assess current market trends, including the rising emphasis on less invasive surgical methods and the ongoing innovations in healthcare technologies. A focus on these dynamics may present UFP as a promising option for those looking to invest in the healthcare supply chain.

Moreover, analysts will be keenly evaluating revenue growth metrics, particularly in relation to both year-over-year performance and quarter-over-quarter trends. Given the broader economic environment, watching for profitability margins in response to possible inflationary pressures could provide valuable insights.

The timing of the earnings report also presents an opportunity for investors to react to conference call discussions led by CFO Ron Lataille, focusing on future guidance, potential acquisitions, and R&D advancements that UFP may be undertaking.

For those considering their position in UFP, it may be prudent to wait for the earnings announcement and the insights offered during the conference call before making any significant investment decisions. The earnings report could reveal critical information that indicates UFP’s trajectory moving forward, influenced by industry shifts and internal strategies. Overall, remain vigilant of the market’s response post-announcement for potential buying or selling opportunities.